INTRODUCTION
Coronavirus is a respiratory disease that is spreading worldwide. The severity and risk of death are important in the elderly, those with comorbidities, and immunosuppressed patients. The outbreak of a pandemic has created significant barriers to the diagnosis, treatment, and monitoring of chronic disease. The provision of regular, planned comprehensive care for chronic patients has been disrupted due to medical facility closures, lack of public transportation, or reduced services. This allowed us to identify rare conditions that would not normally appear 1,2. Graves’ disease is the most common cause of hyperthyroidism in iodine-deficient areas, with an incidence of 21 cases per 100,000 people per year 3. In addition to the signs and symptoms of hyperthyroidism, Graves’ disease can also include Graves’ o orbitopathy disease (GO), thyroid dermatopathy (or pretibial myxoma) (PTM), and thyroid acromopathy5. Rarely, people with Graves’ disease develop Graves’ dermopathy. This is a condition of the skin that is characterized by red, swollen skin, usually on the shins and tips of the feet. There are similarities between the histological features and pathogenesis of GO and PTM 5. In both cases, glycosaminoglycan and mucin substances accumulate5. In both cases, fibroblast proliferation is observed. However, in dermatopathy, lymphocyte proliferation is less pronounced. The onset of thyroid dermatopathy occurs on average 12-24 months after diagnosis of thyrotoxicosis following GO, but in some cases, it can occur many years after diagnosis of hyperthyroidism6.